Yescarta
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Revenues for the firm's antibody-drug conjugate Trodelvy grew 39 percent year over year in Q1 2024 due to increased demand.
FDA Requires Boxed Warning of Secondary Cancer Risk for Autologous CAR T-Cell Therapies
The requirement comes after FDA investigated data showing patients developed secondary T-cell malignancies after CD19- and BCMA-directed CAR T-cell therapies.
Sales of the firm's TROP2-directed antibody-drug conjugate climbed 56 percent year over year thanks to increased demand among breast and bladder cancer patients.
Researchers Showcase New Scores, Biomarkers, Signatures for Predicting CAR T-Cell Outcomes at ASH
Premium
Across three studies, researchers demonstrated how various biomarkers can inform trial design and predict lymphoma patients' outcomes on CAR T-cell therapy.
Aug 4, 2023